Newsroom

BRUXELLES--(BUSINESS WIRE)--Regulatory News: Winamp Group (Paris: ALWIN) (Brussels: ALWIN), société mère de Winamp, annonce une nouvelle série d’accords stratégiques pour Bridger, sa plateforme de gestion des droits d’auteur, marquant une nouvelle étape majeure vers une couverture mondiale complète des droits musicaux sur des marchés stratégiques. À la suite de deux premières vagues de partenariats annoncées ces dernières semaines, Bridger poursuit son accélération avec la signature de nouveaux...

BRUSSELS--(BUSINESS WIRE)--Regulatory News: Winamp Group (Paris: ALWIN) (Brussels: ALWIN), the parent company of Winamp, announces a new series of strategic agreements for Bridger, its copyright management platform, marking another major step toward comprehensive global rights coverage across strategic markets. Following two initial waves of partnerships announced in recent weeks, Bridger continues to scale rapidly, securing additional agreements with leading collective management organizations...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 06.05.2026 UNCU.LN IE00BD6GCF16 801,374.00 USD 37,000,119.98 46.171  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 06.05.2026 UINC IE00BZBW4Z27 10,134,104.00 USD 389,543,302.51 38.439  ...

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD, éligible PEA-PME), entreprise innovante qui déploie sa technologie digitale de guidage chirurgical (DSG®) par mesure locale de la conductivité électrique des tissus en temps réel pour sécuriser et simplifier le placement d’implants osseux, annonce la tenue de son Assemblée Générale Mixte le mercredi 27 mai 2026 à 10h dans les locaux du cabinet d'avocats Chammas et Marcheteau situés 5/6 Villa Ballu (accès...

BARCELONA, Spain--(BUSINESS WIRE)--The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of...

WILLOW PARK, Texas--(BUSINESS WIRE)--ProFrac Holding Corp. (NASDAQ: ACDC) (“ProFrac”, or the “Company”) today announced financial and operational results for its 2026 first quarter ended March 31, 2026. First Quarter 2026 Results Total revenue was $450 million compared to fourth quarter revenue of $437 million Net loss was $81 million compared to net loss of $141 million in the fourth quarter Adjusted EBITDA¹ was $54 million compared to $61 million in the fourth quarter; 12% of revenue in the f...

STOCKHOLM--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Swedbank Robur Fonder AB (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be na...

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, CO. The presentation will highlight early evidence of improvements in visual function, optic nerve pathology, and neurological symptoms in patients with ROSAH syndrome, a rare genetic...